Targeting MAPK signalling: Prometheus' fire or pandora's box?

Current Pharmaceutical Design

Volumn 10, Issue 16, 2004, Pages 1885-1905

  Boldt, Simone ^a   Kolch, Walter ^a,b  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Clinical trials; Drug discovery; ERK; JNK; Mitogen Activated Protein Kinase; p38; Signal transduction

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [4 (4 FLUOROPHENYL) 1 (3 PHENYLPROPYL) 5 (4 PYRIDINYL) 1H IMIDAZOL 2 YL] 3 BUTYN 1 OL; 6 (4 FLUOROPHENYL) 2,3 DIHYDRO 5 (4 PYRIDYL)IMIDAZO[2,1 B]THIAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTISENSE OLIGONUCLEOTIDE; CGP 69846A; CISPLATIN; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; L 779450; LONAFARNIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOMYCIN; N [5 (3 DIMETHYLAMINOBENZAMIDO) 2 METHYLPHENYL] 4 HYDROXYBENZAMIDE; OXINDOLE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN INHIBITOR; RAF PROTEIN; SORAFENIB; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; TAXANE DERIVATIVE; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APOPTOSIS; ASTHMA; BIOCHEMISTRY; BREAST CANCER; CELL CYCLE; CELL MEMBRANE PERMEABILITY; CLINICAL TRIAL; COLORECTAL CANCER; DRUG POTENTIATION; DRUG RESEARCH; DRUG TARGETING; ENDOTOXEMIA; EPILEPSY; GENE MUTATION; HUMAN; LUNG CANCER; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; STROKE; TRANSCRIPTION REGULATION;

ANIMALS; DRUG DELIVERY SYSTEMS; ENZYME INHIBITORS; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES;

EID: 2442469277     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043384420     Document Type: Review

References (263)

1. Cooper JA, Hunter T. Changes in protein phosphorylation in Rous sarcoma virus-transformed chicken embryo cells. Mol Cell Biol 1981; 1(2): 165-78.
2. Cooper JA, Bowen-Pope DF, Raines E, Ross R, Hunter T. Similar effects of platelet-derived growth factor and epidermal growth factor on the phosphorylation of tyrosine in cellular proteins. Cell 1982; 31(1): 263-73.
3. Kazlauskas A, Cooper JA. Protein kinase C mediates platelet-derived growth factor-induced tyrosine phosphorylation of p42. J Cell Biol 1988; 106(4): 1395-402.
4. Rossomando AJ, Payne DM, Weber MJ, Sturgill TW. Evidence that pp42, a major tyrosine kinase target protein, is a mitogen-activated serine/threonine protein kinase. Proc Natl Acad Sci USA 1989; 86(18): 6940-3.
5. Ahn NG, Krebs EG. Evidence for an epidermal growth factor-stimulated protein kinase cascade in Swiss 3T3 cells. Activation of serine peptide kinase activity by myelin basic protein kinases in vitro. J Biol Chem 1990; 265(20): 11495-501.
6. Boulton TG, Yancopoulos GD, Gregory JS, Slaughter C, Moomaw C, Hsu J, et al. An insulin-stimulated protein kinase similar to yeast kinases involved in cell cycle control. Science 1990; 249(4964): 64-7.
7. Courchesne WE, Kunisawa R, Thorner J. A Putative protein kinase overcomes pheromone-induced arrest of cell cycling in S. cerevisiae. Cell 1989; 58(6): 1107-19.
8. Elion EA, Grisafi PL, Fink GR. FUS3 encodes a cdc2+/CDC28-related kinase required for the transition from mitosis into conjugation. Cell 1990; 60(4): 649-64.
9. Boulton TG, Nye SH, Robbins DJ, Ip NY, Radziejewska E, Morgenbesser SD, et al. ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell 1991; 65(4): 663-75.
10. Agrawal GK, Iwahashi H, Rakwal R. Rice MAPKs. Biochem Biophys Res Commun 2003; 302(2): 171-80.
11. Brewster JL, de Valoir T, Dwyer ND, Winter E, Gustin MC. An osmosensing signal transduction pathway in yeast. Science 1993; 259(5102): 1760-3.
12. Lee KS, Irie K, Gotoh Y, Watanabe Y, Araki H, Nishida E, et al. A yeast mitogen-activated protein kinase homolog (Mpk1p) mediates signalling by protein kinase C. Mol Cell Biol 1993; 13(5): 3067-75.
13. Kyriakis JM, Banerjee P, Nikolakaki E, Dai T, Rubie EA, Ahmad MF, et al. The stress-activated protein kinase subfamily of c-Jun kinases. Nature 1994; 369(6476): 156-60.
14. Derijard B, Hibi M, Wu IH, Barrett T, Su B, Deng T, et al. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 1994; 76(6): 1025-37.
15. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994; 372(6508): 739-46.
16. Han J, Lee JD, Bibbs L, Ulevitch RJ. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 1994; 265(5173): 808-11.
17. Rouse J, Cohen P, Trigon S, Morange M, Alonso-Llamazares A, Zamanillo D, et al. A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins. Cell 1994; 78(6): 1027-37.
18. Chen Z, Gibson TB, Robinson F, Silvestro L, Pearson G, Xu B, et al. MAP Kinases. Chem Rev 2001; 101(8): 2449-76.
19. Hindley A, Kolch W. Extracellular signal regulated kinase (ERK)/mitogen activated protein kinase (MAPK)-independent functions of Raf kinases. J Cell Sci 2002; 115(Pt 8): 1575-81.
20. Woodrow MA, Woods D, Cherwinski LIM, Stokoe D, McMahon M. Ras-induced serine phosphorylation of the focal adhesion protein paxillin is mediated by the Raf-->MEK-->ERK pathway. Exp Cell Res 2003; 287(2): 325-38.
21. Deacon K, Blank JL. MEK kinase 3 directly activates MKK6 and MKK7, specific activators of the p38 and c-Jun NH2-terminal kinases. J Biol Chem 1999; 274(23): 16604-10.
22. Xia Y, Makris C, Su B, Li E, Yang J, Nemerow GR, et al. MEK kinase 1 is critically required for c-Jun N-terminal kinase activation by proinflammatory stimuli and growth factor-induced cell migration. Proc Natl Acad Sci USA 2000; 97(10): 5243-8.
23. Lange-Carter CA, Pleiman CM, Gardner AM, Blumer KJ, Johnson GL. A divergence in the MAP kinase regulatory network defined by MEK kinase and Raf. Science 1993; 260(5106): 315-9.
24. Cuenda A, Dorow DS. Differential activation of stress-activated protein kinase kinases SKK4/MKK7 and SKK1/MKK4 by the mixed-lineage kinase-2 and mitogen-activated protein kinase kinase (MKK) kinase-1. Biochem J 1998; 333 (Pt 1): 11-5.
25. Yujiri T, Fanger GR, Garrington TP, Schlesinger TK, Gibson S, Johnson GL. MEK kinase 1 (MEKK1) transduces c-Jun NH2-terminal kinase activation in response to changes in the microtubule cytoskeleton. J Biol Chem 1999; 274(18): 12605-10.
26. Kwan R, Burnside J, Kurosaki T, Cheng G. MEKK1 is essential for DT40 cell apoptosis in response to microtubule disruption. Mol Cell Biol 2001; 21(21): 7183-90.
27. Widmann C, Gibson S, Jarpe MB, Johnson GL. Mitogen-activated protein kinase: conservation ofa three-kinase module from yeast to human. Physiol Rev 1999; 79(1): 143-80.
28. Dickens M, Rogers JS, Cavanagh J, Raitano A, Xia Z, Halpern JR, et al. A cytoplasmic inhibitor of the JNK signal transduction pathway. Science 1997, 277(5326): 693-6.
29. Boulton TG, Yancopoulos GD, Gregory JS, Slaughter C, Moomaw C, Hsu J, et al. An insulin-stimulated protein kinase similar to yeast kinases involved in cell cycle control. Science 1990; 249(4964): 64-67.
30. Lewis TS, Shapiro PS, Ahn NG. Signal transduction through MAP kinase cascades. Adv Cancer Res 1998; 74: 49-139.
31. Kolch W, Kotwaliwale A, Janosch P, Vass K. The role of Raf kinases in malignant transformation. Exp Rev Mol Med 2002; 2002: 1-18. Ref Type: Generic.
32. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000; 19(56): 6550-65.
33. Marshall C. How do small GTPase signal transduction pathways regulate cell cycle entry? Curr Opin Cell Biol 1999; 11(6): 732-36.
34. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417(6892): 949-54.
35. Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, Blalock WL, et al. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 2003; 17(7): 1263-93.
36. Dhillon AS, Kolch W. Untying the regulation of the Raf-1 kinase. Arch Biochem Biophys 2002; 404(1): 3-9.
37. Vikis H, Guan KL. Regulation of the Ras-MAPK pathway at the level of Ras and Raf. Genet Eng (NY) 2002; 24: 49-66.
38. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001; 22(2): 153-83.
39. Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, Blalock WL, et al. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 2003; 17(7): 1263-93.
40. TCF by MAP kinase stimulates ternary complex formation at c-fos promoter. Nature 1992; 358: 414-17.
41. Murphy LO, Smith S, Chen RH, Fingar DC, Blenis J. Molecular interpretation of ERK signal duration by immediate early gene products. Nat Cell Biol 2002; 4(8): 556-64.
42. Treinies I, Paterson HF, Hooper S, Wilson R, Marshall CJ. Activated MEK stimulates expression of AP-1 components independently of phosphatidylinositol 3-kinase (PI3-kinase) but requires a PI3-kinase signal To stimulate DNA synthesis. Mol Cell Biol 1999; 19(1): 321-29.
43. Cook SJ, Aziz N, McMahon M. The repertoire of fos and jun proteins expressed during the G1 phase of the cell cycle is determined by the duration of mitogen-activated protein kinase activation. Mol Cell Biol 1999; 19(1): 330-41.
44. Vial E, Sahai E, Marshall CJ. ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility. Cancer Cell 2003; 4(1): 67-79.
45. Shaulian E, Karin M. AP-1 in cell proliferation and survival. Oncogene 2001; 20(19): 2390-400.
46. Kieser A, Seitz T, Adler HS, Coffer P, Kremmer E, Crespo P, et al. Protein kinase C-zeta reverts v-raf transformation of NIH-3T3 cells. Genes Dev 1996; 10(12): 1455-66.
47. Passegue E, Jochum W, Behrens A, Ricci R, Wagner EF. JunB can substitute for Jun in mouse development and cell proliferation. Nat Genet 2002; 30(2): 158-66.
48. Askew DS, Ashmum RA, Simmons BC, Cleveland JL. Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene 1991; 6(10): 1915-22.
49. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992; 69(1): 119-28.
50. Cleveland JL, Jansen HW, Bister K, Fredrickson TN, Morse HC, Ihle JN, et al. Interaction between Raf and Myc oncogenes in transformation in vivo and in vitro. J Cell Biochem 1986; 30: 195-218.
51. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev 2000; 14(19): 2501-14.
52. Weissinger EM, Eissner G, Grammer C, Fackler S, Haefner B, Yoon LS, et al. Inhibition of the Raf-1 kinase by cyclic AMP agonists causes apoptosis of v-abl-transformed cells. Mol Cell Biol 1997; 17: 3229-41.
53. Soloaga A, Thomson S, Wiggin GR, Rampersaud N, Dyson MH, Hazzalin CA, et al. MSK2 and MSK1 mediate the mitogen- and stress-induced phosphorylation of histone H3 and HMG-14. EMBO J 2003; 22(11): 2788-97.
54. Zhou X, Richon VM, Wang AH, Yang XJ, Rifkind RA, Marks PA. Histone deacetylase 4 associates with extracellular signal-regulated kinases 1 and 2, and its cellular localization is regulated by oncogenic Ras. Proc Natl Acad Sci USA 2000; 97(26): 14329-33.
55. Marshall C. How do small GTPase signal transduction pathways regulate cell cycle entry? Curr Opin Cell Biol 1999; 11(6): 732-36.
56. McMahon M, Woods D. Regulation of the p53 pathway by Ras, the plot thickens. Biochim Biophys Acta 2001; 1471(2): M63-M71.
57. Roper E, Weinberg W, Watt FM, Land H. p19ARF-independent induction of p53 and cell cycle arrest by Raf in murine keratinocytes. EMBO Rep 2001; 2(2): 145-50.
58. Ravi RK, Weber E, McMahon M, Williams JR, Baylin S, Mal A, et al. Activated Raf-1 causes growth arrest in human small cell lung cancer cells. J Clin Invest 1998; 101: 153-9.
59. Willard FS, Crouch MF. MEK, ERK, and p90RSK are present on mitotic tubulin in Swiss 3T3 cells: a role for the MAP kinase pathway in regulating mitotic exit. Cell Signal 2001; 13(9): 653-64.
60. Yan X, Li F, Liang Y, Shen Y, Zhao X, Huang Q, et al. Human Nudel and NudE as regulators of cytoplasmic dynein in poleward protein transport along the mitotic spindle. Mol Cell Biol 2003; 23(4): 1239-50.
61. Horne MM, Guadagno TM. A requirement for MAP kinase in the assembly and maintenance of the mitotic spindle. J Cell Biol 2003: 161(6): 1021-8.
62. Chung E, Chen RH. Phosphorylation of Cdc20 is required for its inhibition by the spindle checkpoint. Nat Cell Biol 2003; 5(8): 748-53.
63. Saavedra HI, Fukasawa K, Conn CW, Stambrook PJ. MAPK mediates RAS-induced chromosome instability. J Biol Chem 1999; 274(53): 38083-90.
64. Wang LG, Liu XM, Kreis W, Budman DR. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol 1999; 44(5): 355-61.
65. Wiese S, Pei G, Karch C, Troppmair J, Holtmann B, Rapp UR, et al. Specific function of B-Raf in mediating survival of embryonic motoneurons and sensory neurons. Nat Neurosci 2001; 4(2): 137-42.
66. Bonni A, Brunet A, West AE, Datta SR, Takasu MA, Greenberg ME. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 1999; 286(5443): 1358-62.
67. Allan LA, Morrice N, Brady S, Magee G, Pathak S, Clarke PR. Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK. Nat Cell Biol 2003; 5(7): 647-54.
68. Tuszynski MH, Thal L, U HS, Pay MM, Blesch A, Conner J, et al. Nerve growth factor gene therapy for Alzheimer's disease. J Mol Neurosci 2002; 19(1-2): 207.
69. Anderson CN, Tolkovsky AM. A role for MAPK/ERK in sympathetic neuron survival: protection against a p53-dependent, JNK-independent induction of apoptosis by cytosine arabinoside. J Neurosci 1999; 19(2): 664-73.
70. Hughes PE, Oertli B, Hansen M, Chou FL, Willumsen BM, Ginsberg MH. Suppression of integrin activation by activated Ras or Raf does not correlate with bulk activation of ERK MAP kinase. Mol Biol Cell 2002; 13(7): 2256-65.
71. Akimov SS, Belkin AM. Opposing Roles of Ras/Raf Oncogenes and the MEK1/ERK Signaling Module in Regulation of Expression and Adhesive Function of Surface Transglutaminase. J Biol Chem 2003; 278(37): 35609-19.
72. Chen J, Fujii K, Zhang L, Roberts T, Fu H. Raf-1 promotes cell survival by antagonizing apoptosis signal- regulating kinase 1 through a MEK-ERK independent mechanism. Proc Natl Acad Sci USA 2001; 98(14): 7783-8.
73. Broustas CG, Grammatikakis N, Eto M, Dent P, Brautigan D, Kasid U. Phosphorylation of myosin-binding subunit of myosin phosphatase by Raf-1 and inhibition of phosphatase activity. J Biol Chem 2001; 277: 3053-9.
74. Janosch P, Kieser A, Eulitz M, Lovric J, Sauer G, Reichert M, et al. The Raf-1 kinase associates with vimentin kinases and regulates the structure of vimentin filaments. FASEB J 2000; 14(13): 2008-21.
75. Huser M, Luckett J, Chiloeches A, Mercer K, Iwobi M, Giblett S, et al. MEK kinase activity is not necessary for Raf-1 function. EMBO J 2001; 20(8): 1940-51.
76. Mikula M, Schreiber M, Husak Z, Kucerova L, Ruth J, Wieser R, et al. Embryonic lethality and fetal liver apoptosis in mice lacking the c-raf-1 gene. EMBO J 2001; 20(8): 1952-62.
77. Pritchard CA, Bolin L, Slattery R, Murray R, McMahon M. Postnatal lethality and neurological and gastrointestinal defects in mice with targeted disruption of the A-Raf protein kinase gene. Curr Biol 1996; 6(5): 614-7.
78. Wojnowski L, Zimmer AM, Beck TW, Hahn H, Bernal R, Rapp UR, et al. Endothelial apoptosis in Braf-deficient mice. Nat Genet 1997; 16(3): 293-7.
79. Wojnowski L, Stancato LF, Zimmer AM, Hahn H, Beck TW, Larner AC, et al. Craf-1 protein kinase is essential for mouse development. Mech Dev 1998; 76(1-2): 141-9.
80. Giroux S, Tremblay M, Bernard D, Cardin-Girard JF, Aubry S, Larouche L, et al. Embryonic death of Mek 1-deficient mice reveals a role for this kinase in angiogenesis in the labyrinthine region of the placenta. Curr Biol 1999; 9(7): 369-72.
81. Pages G, Guerin S, Grall D, Bonino F, Smith A, Anjuere F, et al. Defective thymocyte maturation in p44 MAP kinase (Erk 1) knockout mice. Science 1999; 286(5443): 1374-7.
82. Pouyssegur J, Lenormand P. Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling. Eur J Biochem 2003; 270(16): 3291-9.
83. Montes M, Tagieva NE, Heveker N, Nahmias C, Baleux F, Trautmann A. SDF-1-induced activation of ERK enhances HIV-1 expression. Eur Cytokine Netw 2000; 11(3): 470-7.
84. Pleschka S, Wolff T, Ehrhardt C, Hobom G, Planz O, Rapp UR, et al. Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade. Nat Cell Biol 2001; 3(3): 301-5.
85. Rapoport M, Ferreira A, PD98059 prevents neurite degeneration induced by fibrillar beta-amyloid in mature hippocampal neurons. J Neurochem 2000; 74(1): 125-33.
86. Clerk A, Sugden PH. Activation of protein kinase cascades in the heart by hypertrophic G protein-coupled receptor agonists. Am J Cardiol 1999; 83(12A): 64H-69H.
87. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989; 49(17): 4682-9.
88. Kolch W. Ras/Raf signalling and emerging pharmacotherapeutic targets. Expert Opin Pharmacother 2002; 3(6): 709-18.
89. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001; 93(14): 1062-74.
90. Gibbs RA, Zahn TJ, Sebolt-Leopold JS. Non-peptidic prenyltransferase inhibitors: diverse structural classes and surprising anti-cancer mechanisms. Curr Med Chem 2001; 8(12): 1437-65.
91. Sebti SM, Hamilton AD. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene 2000; 19(56): 6584-93.
92. Sun J, Qian Y, Hamilton AD, Sebti SM. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts. Oncogene 1998; 16(11): 1467-73.
93. Prendergast GC, Rane N. Farnesyltransferase inhibitors: mechanism and applications. Expert Opin Investig Drugs 2001; 10(12): 2105-16.
94. Kelland LR. Farnesyl transferase inhibitors in the treatment of breast cancer. Expert Opin Investig Drugs 2003; 12(3): 413-21.
95. Sun J, Blaskovich MA, Knowles D, Qian Y, Ohkanda J, Bailey RD, et al. Antitumor efficacy of a novel class of non-thiol- containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine. Cancer Res 1999; 59(19): 4919-26.
96. Flaherty KT, Stevenson JP, O'Dwyer PJ. Antisense therapeutics: lessons from early clinical trials. Curr Opin Oncol 2001; 13(6): 499-05.
97. Cunningham CC, Holmlund JT, Geary RS, Kwoh TJ, Dorr A, Johnston JF, et al. A Phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma. Cancer 2001; 92(5): 1265-71.
98. Zhang YA, Nemunaitis J, Scanlon KJ, Tong AW. Anti-tumorigenic effect of a K-ras ribozyme against human lung cancer cell line heterotransplants in nude mice. Gene Ther 2000; 7(23): 2041-50.
99. Brummelkamp TR, Bernards R, Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002; 2(3): 243-47.
100. Khleif SN, Abrams SI, Hamilton JM, Bergmann-Leitner E, Chen A, Bastian A, et al. A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors. J Immunother 1999; 22(2): 155-65.
101. Clark GJ, Drugan JK, Terrell RS, Bradham C, Der CJ, Bell RM, et al. Peptides containing a consensus Ras binding sequence from Raf-1 and the GTPase activating protein NF1 inhibit Ras function, Proc Natl Acad Sci USA 1996; 93: 1577-81.
102. Kimoto M, Shirouzu M, Mizutani S, Koide H, Kaziro Y, Hirao I, et al. Anti-(Raf-1) RNA aptamers that inhibit Ras-induced Raf-1 activation. Eur J Biochem 2002; 269(2): 697-04.
103. Kato-Stankiewicz J, Hakimi I, Zhi G, Zhang J, Serebriiskii I, Guo L, et al. Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells. Proc Natl Acad Sci USA 2002; 99(22): 14398-403.
104. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417(6892): 949-54.
105. Hall-Jackson CA, Eyers PA, Cohen P, Goedert M, Boyle FT, Hewitt N, et al. Paradoxical activation of Raf by a novel Raf inhibitor. Chem Biol 1999; 6: 559-68.
106. Wood E, Crosby RM, Dickerson S, Frye SV, Griffin R, Hunter R, et al. A prodrug approach to the design of cRaf1 kinase inhibitors with improved cellular activity. Anticancer Drug Des 2001; 16(1): 1-6.
107. Heimbrook DC, Huber HE, Stirdivant SM, Patrick DR, Claremon D, Liverton N, et al. Identification of potent, selective inhibitors of Raf. Proc Amer Assoc Cancer Res 1998; 39: 3793. Ref Type: Generic.
108. Lyons JF, Wilhelm S, Hibner B, Bollag G. Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 2001; 8(3): 219-25.
109. Strumberg D, Voliotis D, Moeller JG, Hilger RA, Richly H, Kredtke S, et al. Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors. Int J Clin Pharmacol Ther 2002; 40(12): 580-1.
110. Hotte SJ, Hirte HW. BAY 43-9006: early clinical data in patients with advanced solid malignancies. Curr Pharm Des 2002; 8(25): 2249-53.
111. Rudin CM, Holmlund J, Fleming GF, Mani S, Stadler WM, Schumm P, et al. Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. Clin Cancer Res 2001; 7(5): 1214-20.
112. Holmlund JT, Monia BP, Kwoh TJ, Dorr FA. Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development. Curr Opin Mol Ther 1999; 1(3): 372-85.
113. Oza AM, Elit L, Swenerton K, Faught W, Ghatage P, Carey M, et al. Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116). Gynecol Oncol 2003; 89(1): 129-33.
114. Tolcher AW, Reyno L, Venner PM, Ernst SD, Moore M, Geary RS, et al. A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer. Clin Cancer Res 2002: 8(8): 2530-35.
115. Cripps MC, Figueredo AT, Oza AM, Taylor MJ, Fields AL, Holmlund JT, et al. Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study. Clin Cancer Res 2002; 8(7): 2188-92.
116. Stepkowski SM, QU X, Wang ME, Tian L, Chen W, Wancewicz EV, et al. Inhibition of C-raf expression by antisense oligonucleotides extends heart allograft survival in rats. Transplantation 2000; 70(4): 656-61.
117. Workman P, Maloney A. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther 2002; 2(1): 3-24.
118. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR. PD 098059 is a specific inhibitor of' the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 1995; 270: 27489-94.
119. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase [In Process Citation]. J Biol Chem 1998; 273: 18623-32.
120. Delaney AM, Printen JA, Chen H, Fauman EB, Dudley DT. Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352. Mot Cell Biol 2002; 22(21): 7593-602.
121. Mody N, Leitch J, Armstrong C, Dixon J, Cohen P. Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway. FEBS Lett 2001; 502(1-2): 21-4.
122. Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 1999; 5(7): 810-6.
123. Zhang N, Wu B, Powell D, Wissner A, Floyd MB, Kovacs ED, et al. Synthesis and structure-activity relationships of 3-cyano-4-(phenoxyanilino)quinolines as MEK (MAPKK) inhibitors. Bioorg Med Chem Lett 2000; 10(24): 2825-8.
124. Zhao A, Lee SH, Mojena M, Jenkins RG, Patrick DR, Huber HE, et al. Resorcylic acid lactones: naturally occurring potent and selective inhibitors of MEK. J Antibiot (Tokyo) 1999; 52: 1086-94.
125. Williams DH, Wilkinson SE, Purton T, Lamont A, Flotow H, Murray EJ. Ro 09-2210 exhibits potent anti-proliferative effects on activated T cells by selectively blocking MKK activity. Biochemistry 1998; 37(26): 9579-85.
126. Hibi M, Lin A, Smeal T, Minden A, Karin M. Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain Genes Dev 1993; 7(11); 2135-48.
127. Sanchez I, Hughes RT, Mayer BJ, Yee K, Woodgett JR, Avruch J, et al. Role of SAPK/ERK kinase-1 in the stress-activated pathway regulating transcription factor c-Jun. Nature 1994; 372(6508): 794-8.
128. Yan M, Dai T, Deak JC, Kyriakis JM, Zon LI, Woodgett JR, et al. Activation of stress-activated protein kinase by MEKK1 phosphorylation of its activator SEK1. Nature 1994; 372(6508): 798-800.
129. Gupta S, Barrett T, Whitmarsh AJ, Cavanagh J, Sluss HK, Derijard B, et al. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J 1996; 15(11): 2760-70.
130. Weston CR, Davis RJ. The JNK signal transduction pathway. Curr Opin Genet Dev 2002; 12(1): 14-21.
131. Karin M. Mitogen-activated protein kinase cascades as regulators of stress responses. Ann N Y Acad Sci 1998; 851: 139-46.
132. Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001; 81(2): 807-69.
133. Manning AM, Davis RJ. Targeting JNK for therapeutic benefit: from junk to gold? Nat Rev Drug Discov 2003; 2(7): 554-65.
134. Kallunki T, Deng T, Hibi M, Karin M. c-Jun can recruit JNK to phosphorylate dimerization partners via specific docking interactions. Cell 1996; 87(5): 929-39.
135. Papavassiliou AG, Treier M, Bohmann D. Intramolecular signal transduction in c-Jun. EMBO J 1995; 14(9): 2014-9.
136. Morton S, Davis RJ, McLaren A, Cohen P. A reinvestigation of the multisite phosphorylation of the transcription factor c-Jun. EMBO J 2003; 22(15): 3876-86.
137. Weiss C, Schneider S, Wagner EF, Zliang X, Seto E, Bohmann D. JNK phosphorylation relieves HDAC3-dependent suppression of the transcriptional activity of c-Jun. EMBO J 2003; 22(14): 3686-95.
138. Jiang Y, Chen C, Li Z, Guo W, Gegner JA, Lin S, et al. Characterization of the structure and function of a new mitogen-activated protein kinase (p38beta). J Biol Chem 1996; 271(30): 17920-6.
139. Fuchs SY, Tappin I, Ronai Z. Stability of the ATF2 transcription factor is regulated by phosphorylation and dephosphorylation. J Biol Chem 2000; 275(17): 12560-4.
140. Dai R, Frejtag W, He B, Zhang Y, Mivechi NF. c-Jun NH2-terminal kinase targeting and phosphorylation of heat shock factor-1 suppress its transcriptional activity. J Biol Chem 2000; 275(24): 18210-8.
141. Chow CW, Dong C, Flavell RA, Davis RJ. c-Jun NH(2)-terminal kinase inhibits targeting of the protein phosphatase calcineurin to NFATcl. Mol Cell Biol 2000; 20(14): 5227-34.
142. Chow CW, Rincon M, Cavanagh J, Dickens M, Davis RJ. Nuclear accumulation of NFAT4 opposed by the JNK signal transduction pathway. Science 1997; 278(5343): 1638-41.
143. Aguirre V, Uchida T, Yenush L, Davis R, White MF. The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem 2000; 275(12): 9047-54.
144. Fujishiro M, Gotoh Y, Katagiri H, Sakoda H, Ogihara T, Anai M, et al. Three mitogen-activated protein kinases inhibit insulin signaling by different mechanisms in 3T3-L1 adipocytes. Mol Endocrinol 2003; 17(3): 487-97.
145. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995; 270: 1326-31.
146. Boldt S, Weidle UH, Kolch W. The role of MAPK pathways in the action of chemotherapeutic drugs. Carcinogenesis 2002; 23(11): 1831-8.
147. Nishina H, Vaz C, Billia P, Nghiem M, Sasaki T, De la Pompa JL, et al. Defective liver formation and liver cell apoptosis in mice lacking the stress signaling kinase SEK1/MKK4. Development 1999; 126(3): 505-16.
148. Lamb JA, Ventura JJ, Hess P, Flavell RA, Davis RJ. JunD mediates survival signaling by the JNK signal transduction pathway. Mol Cell 2003; 11(6): 1479-89.
149. Lei K, Davis RJ. JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis. Proc Natl Acad Sci USA 2003; 100(5): 2432-7.
150. Donovan N, Becker EB, Konishi Y, Bonni A. JNK phosphorylation and activation of BAD couples the stress-activated signaling pathway to the cell death machinery. J Biol Chem 2002; 277(43): 40944-9.
151. Basu A, Haldar S. Identification of a novel Bcl-xL phosphorylation site regulating the sensitivity of taxol- or 2-methoxyestradiol-induced apoptosis. FEBS Lett 2003; 538(1-3): 41-7.
152. Yamamoto K, Ichijo H, Korsmeyer SJ. BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol Cell Biol 1999; 19(12): 8469-78.
153. Lei K, Nimnual A, Zong WX, Kennedy NJ, Flavell RA, Thompson CB, et al. The Bax subfamily of Bcl2-related proteins is essential for apoptotic signal transduction by c-Jun NH(2)-terminal kinase. Mol Cell Biol 2002; 22(13): 4929-42.
154. Yujiri T, Sather S, Fanger GR, Johnson GL. Role of MEKK1 in cell survival and activation of JNK and ERK pathways defined by targeted gene disruption. Science 1998; 282(5395): 1911-4.
155. Yujiri T, Ware M, Widmann C, Oyer R, Russell D, Chan E, et al. MEK kinase 1 gene disruption alters cell migration and c-Jun NH2-terminal kinase regulation but does not cause a measurable defect in NF-kappa B activation. Proc Natl Acad Sci USA 2000; 97(13): 7272-7.
156. Xia Y, Makris C, Su B, Li E, Yang J, Nemerow GR, et al. MEK kinase 1 is critically required for c-Jun N-terminal kinase activation by proinflammatory stimuli and growth factor-induced cell migration. Proc Natl Acad Sci USA 2000; 97: 5243-8.
157. Kwan R, Burnside J, Kurosaki T, Cheng G. MEKK1 is essential for DT40 cell apoptosis in response to microtubule disruption. Mol Cell Biol 2001; 21: 7183-90.
158. Ganiatsas S, Kwee L, Fujiwara Y, Perkins A, Ikeda T, Labow MA. et al. SEK1 deficiency reveals mitogen-activated protein kinase cascade crossregulation and leads to abnormal hepatogenesis. Proc Natl Acad Sci USA 1998; 95(12): 6881-6.
159. Yang D, Tournier C, Wysk M, Lu HT, Xu J, Davis RJ, et al. Targeted disruption of the MKK4 gene causes embryonic death, inhibition of c-Jun NH2-terminal kinase activation, and defects in AP-1 transcriptional activity. Proc Natl Acad Sci USA 1997; 94(7): 3004-9.
160. Dong C, Yang DD, Tournier C, Whitmarsh AJ, Xu J, Davis RJ, et al. JNK is required for effector T-cell function but not for T-cell activation. Nature 2000; 405(6782): 91-4.
161. Tournier C, Dong C, Turner TK, Jones SN, Flavell RA, Davis RJ. MKK7 is an essential component of the JNK signal transduction pathway activated by proinflammatory cytokines. Genes Dev 2001; 15(11): 1419-26.
162. Gupta S, Barrett T, Whitmarsh AJ, Cavanagh J, Sluss HK, Derijard B, et al. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J 1996; 15(11): 2760-70.
163. Dong C, Yang DD, Wysk M, Whitmarsh AJ, Davis RJ, Flavell RA. Defective T cell differentiation in the absence of Jnk1. Science 1998; 282(5396): 2092-5.
164. Yang DD, Conze D, Whitmarsh AJ, Barrett T, Davis RJ, Rincon M, et al. Differentiation of CD4+T cells to Th1 cells requires MAP kinase JNK2. Immunity 1998; 9(4): 575-85.
165. Yang DD, Kuan CY, Whitmarsh AJ, Rincon M, Zheng TS, Davis RJ, et al. Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene. Nature 1997; 389(6653): 865-70.
166. Kuan CY, Yang DD, Samanta Roy DR, Davis RJ, Rakic P, Flavell RA. The Jnk1 and Jnk2 protein kinases are required for regional specific apoptosis during early brain development. Neuron 1999; 22(4): 667-76.
167. Weiss L, Whitmarsh AJ, Yang DD, Rincon M, Davis RJ, Flavell RA. Regulation of c-Jun NH(2)-terminal kinase (Jnk) gene expression during T cell activation. J Exp Med 2000; 191(1): 139-46.
168. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W. et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 2001; 98(24): 13681-6.
169. Bain J, McLauchlan H, Elliott M, Cohen P. The specificities of protein kinase inhibitors: an update. Biochem J 2003; 371(Pt 1): 199-204.
170. Han Z, Boyle DL, Chang L, Bennett B, Karin M, Yang L, et al, c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest 2001; 108(1): 73-81.
171. Yasuda J, Whitmarsh AJ, Cavanagh J, Sharma M, Davis RJ. The JIP group of mitogen-activated protein kinase scaffold proteins. Mol Cell Biol 1999; 19(10): 7245-54.
172. Barr RK, Kendrick TS, Bogoyevitch MA. Identification of the critical features of a small peptide inhibitor of JNK activity. J Biol Chem 2002; 277(13): 10987-97.
173. Bonny C, Oberson A, Negri S, Sauser C, Schorderet DF. Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death. Diabetes 2001; 50(1): 77-82.
174. Hall J, Lee JD, Bibbs L, Ulevitch RJ. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 1994; 265(5173): 808-11.
175. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994; 372(6508): 739-46.
176. Lee JC, Kumar S, Griswold DE, Underwood DC, Votta BJ, Adams JL. Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology 2000; 47(2-3): 185-201.
177. Cohen P. The search for physiological substrates for MAP and SAP kinases in mammalian cells. Trends Cell Biol 1997; 7: 353-61. Ref Type: Generic
178. Goedert M, Cuenda A, Craxton M, Jakes R, Cohen P. Activation of the novel stress-activated protein kinase SAPK4 by cytokines and cellular stresses is mediated by SKK3 (MKK6); comparison of its substrate specificity with that of other SAP kinases. EMBO J 1997; 16(12): 3563-71.
179. Cuenda A, Cohen P, Buee-Scherrer V, Goedert M. Activation of stress-activated protein kinase-3 (SAPK3) by cytokines and cellular stresses is mediated via SAPKK3 (MKK6); comparison of the specificities of SAPK3 and SAPK2 (RK/p38). EMBO J 1997; 16(2): 295-305.
180. Bulavin DV, Higashimoto Y, Popoff IJ, Gaarde WA, Basrur V, Potapova O, et al. Initiation ofa G2/M checkpoint after ultraviolet radiation requires p38 kinase. Nature 2001; 411(6833): 102-7.
181. Takenaka K, Moriguchi T, Nishida E. Activation of the protein kinase p38 in the spindle assembly checkpoint and mitotic arrest. Science 1998; 280(5363): 599-602.
182. Rousseau S, Morrice N, Peggie M, Campbell DG, Gaestel M. Cohen P. Inhibition of SAPK2a/p38 prevents hnRNP A0 phosphorylation by MAPKAP-K2 and its interaction with cytokine mRNAs. EMBO J 2002; 21(23): 6505-14.
183. Stokoe D, Caudwell B, Cohen PT, Cohen P. The substrate specificity and structure of mitogen-activated protein (MAP) kinase-activated protein kinase-2. Biochem J 1993; 296(Pt 3): 843-9.
184. McLaughlin MM, Kumar S, McDonnell PC, Van Horn S, Lee JC, Livi GP, et al. Identification of mitogen-activated protein (MAP) kinase-activated protein kinase-3, a novel substrate of CSBP p38 MAP kinase. J Biol Chem 1996; 271(14): 8488-92.
185. Sithanandam G, Latif F, Dub FM, Bernal R, Smola U, Li H, et al. 3pK, a new mitogen-activated protein kinase-activated protein kinase located in the small cell lung cancer tumor suppressor gene region. Mol Cell Biol 1996; 16(3): 868-76.
186. Ni H, Wang XS, Diener K, Yao Z. MAPKAPK5, a novel mitogen-activated protein kinase (MAPK)-activated protein kinase, is a substrate of the extracellular-regulated kinase (ERK) and p38 kinase. Biochem Biophys Res Commun 1998; 243(2): 492-6.
187. Allen M, Svensson L, Roach M, Hambor J, McNeish J, Gabel CA. Deficiency of the stress kinase p38alpha results in embryonic lethality: characterization of the kinase dependence of stress responses of enzyme-deficient embryonic stem cells. J Exp Med 2000; 191(5): 859-70.
188. Clifton AD, Young PR, Cohen P. A comparison of the substrate specificity of MAPKAP kinase-2 and MA13KAP kinase-3 and their activation by cytokines and cellular stress. FEBS Lett 1996; 392(3): 209-14.
189. Parcellier A, Gurbuxani S, Schmitt E, Solary E, Garrido C. Heat shock proteins, cellular chaperones that modulate mitochondrial cell death pathways. Biochem Biophys Res Commun 2003; 304(3): 505-12.
190. Park KJ, Gaynor RB, Kwak YT. Hsp27 association with the IKK complex regulates TNF-alpha -induced NF-kappa B activation. J Biol Chem 2003; 278: 35272-8.
191. Deak M, Clifton AD, Lucocq LM, Alessi DR. Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may mediate activation of CREB. EMBO J 1998; 17(15): 4426-41.
192. Neufeld B, Grosse-Wilde A, Hoffmeyer A, Jordan BW, Chen P, Dinev D, et al. Serine/Threonine kinases 3pK and MAPK-activated protein kinase 2 interact with the basic helix-loop-helix transcription factor E47 and repress its transcriptional activity. J Biol Chem 2000; 275(27): 20239-42.
193. Heidenreich O, Neininger A, Schratt G. Zinck R, Cahill MA, Engel K, et al. MAPKAP kinase 2 phosphorylates serum response factor in vitro and in vivo. J Biol Chem 1999; 274(20): 14434-43.
194. Ben Levy R, Hooper S, Wilson R, Paterson HF, Marshall CJ. Nuclear export of-the stress-activated protein kinase p38 mediated by its substrate MAPKAP kinase-2. Curr Biol 1998; 8(19): 1049-57.
195. New L, Jiang Y, Zhao M, Liu K, Zhu W, Flood LJ, et al. PRAK, a novel protein kinase regulated by file p38 MAP kinase. EMBO J 199; 17(12): 3372-84.
196. Raingeaud J, Whitmarsh AJ, Barrett T, Derijard B, Davis RJ. MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Mol Cell Biol 1996; 16(3): 1247-55.
197. Thuerauf DJ, Arnold ND, Zechner D, Hanford DS, DeMartin KM, McDonough PM, et al. p38 Mitogen-activated protein kinase mediates the transcriptional induction of the atrial natriuretic factor gene through a serum response element. A potential role for the transcription factor ATF6. J Biol Chem 1998; 273(32): 20636-43.
198. Sommer T, Jarosch E. BiP binding keeps ATF6 at bay. Dev Cell 2002; 3(1): 1-2.
199. Friedman AD. GADD153/CHOP, a DNA damage-inducible protein, reduced CAAT/enhancer binding protein activities and increased apoptosis in 32D c13 myeloid cells. Cancer Res 1996; 56(14): 3250-6.
200. Ubeda M, Vallejo M, Habener JF. CHOP enhancement of gene transcription by interactions with Jun/Fos AP-1 complex proteins. Mol Cell Biol 1999; 19(11): 7589-99.
201. Wang XZ, Ron D. Stress-induced phosphorylation and activation of the transcription factor CHOP (GADD153) by p38 MAP Kinase. Science 1996; 272(5266): 1347-9.
202. Black BL, Olson EN. Transcriptional control of muscle development by myocyte enhancer factor-2 (MEF2) proteins. Annu Rev Cell Dev Biol 1998; 14: 167-96.
203. Janknecht R, Hunter T. Convergence of MAP kinase pathways on the ternary complex factor Sap-1a. EMBO J 1997; 16(7): 1620-7.
204. Price MA, Cruzalegui FH, Treisman R. The p38 and ERK MAP kinase pathways cooperate to activate Ternary Complex Factors and c-fos transcription in response to UV light. EMBO J 1996; 15(23): 6552-63.
205. Lavoie JN, L'Allemain G, Brunet A, Muller R, Pouyssegur J. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem 1996; 271(34): 20608-16.
206. Zhang H, Shi X, Hampong M, Blanis L, Pelech S. Stress-induced inhibition of ERK1 and ERK2 by direct interaction with p38 MAP kinase. J Biol Chem 2001; 276(10): 6905-8.
207. Cocolakis E, Lemay S, Ali S, Lebrun JJ. The p38 MAPK pathway is required for cell growth inhibition of human breast cancer cells in response to activin. J Biol Chem 2001; 276(21): 18430-6.
208. Garner AP, Weston CR, Todd DE, Balmanno K, Cook SJ. Delta MFKK3: ER* activation induces a p38 alpha/beta 2-dependent cell cycle arrest at file G2 checkpoint. Oncogene 2002; 21(53): 8089-104.
209. Lu HT, Yang DD, Wysk M, Gatti E, Mellman I, Davis RJ, et al. Defective IL-12 production in mitogen-activated protein (MAP) kinase kinase 3 (Mkk3)-deficient mice. EMBO J 1999; 18(7): 1845-57.
210. Wysk M, Yang DD, Lu HT, Flavell RA, Davis RJ. Requirement of mitogen-activated protein kinase kinase 3 (MKK3) for tumor necrosis factor-induced cytokine expression. Proc Natl Acad Sci USA 1999; 96(7): 3763-8.
211. Winzen R, Kracht M, Ritter B, Wilhelm A, Chen CY, Shyu AB, et al. The p38 MAP kinase pathway signals for cytokine-induced mRNA stabilization via MAP kinase-activated protein kinase 2 and an AU-rich region-targeted mechanism. EMBO J 1999; 18(18): 4969-80.
212. Allen M, Svensson L, Roach M, Hambor J, McNeish J, Gabel CA. Deficiency of the stress kinase p38alpha results in embryonic lethality: characterization of the kinase dependence of stress responses of enzyme-deficient embryonic stem cells. J Exp Med 2000; 191(5): 859-70.
213. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000; 351(Pt 1): 95-105.
214. Gum RJ, McLaughlin MM, Kumar S, Wang Z, Bower MJ, Lee JC, et al. Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP binding pocket. J Biol Chem 1998; 273(25): 15605-10.
215. Eyers PA, Craxton M, Morrice N, Cohen P, Goedert M. Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution. Chem Biol 1998; 5(6): 321-8.
216. Ward KW, Proksch JW, Gorycki PD, Yu CP, Ho MY, Bush BD, et al. SB-242235, a selective inhibitor of p38 mitogen-activated protein kinase. II: in vitro and in vivo metabolism studies and pharmacokinetic extrapolation to man. Xenobiotica 2002; 32(3): 235-50.
217. Ward KW, Proksch JW, Salyers KL, Azzarano LM, Morgan JA, Roethke TJ, et al. SB-242235, a selective inhibitor of p38 mitogen-activated protein kinase. I: preclinical pharmacokinetics. Xenobiotica 2002; 32(3): 221-33.
218. Hideshima T, Akiyama M, Hayashi T, Richardson P, Schlossman R, Chauhan D, et al. Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. Blood 2003; 101(2): 703-5.
219. Haddad JJ. VX-745. Vertex Pharmaceuticals. Curr Opin Investig Drugs 2001; 2(8): 1070-6.
220. Choy, E. Pharmacotherapy beyond Tumour Necrosis Factor Inhibition. http://www.rheuma21st.com/archives/cutting_edge_choy.html 2003.
221. Hideshima T, Akiyama M, Hayashi T, Richardson P, Schlossman R, Chauhan D, et al. Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. Blood 2003; 101(2): 703-5.
222. Dumas J, Sibley R, Riedl B, Monahan MK, Lee W, Lowinger TB, et al. Discovery of a new class of p38 kinase inhibitors. Bioorg Med Chem Lett 2000; 10(18): 2047-50.
223. Pargellis C, Tong L, Churchill L, Cirillo PF, Gilmore T, Graham AG, et al. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Biol 2002; 9(4): 268-72.
224. Branger J, van den Blink B, Weijer S, Madwed J, Bos CL, Gupta A, et al. Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. J Immunol 2002; 168(8): 4070-7.
225. Branger J, van den Blink B, Weijer S, Gupta A, van Deventer SJ, Hack CE, et al. Inhibition of coagulation, fibrinolysis, and endothelial cell activation by a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. Blood 2003; 101(11): 4446-8.
226. Wadsworth SA, Cavender DE, Beers SA, Lalan P, Schafer PH, Malloy EA, et al. RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. J Pharmacol Exp Ther 1999; 291(2): 680-7.
227. Fijen JW, Zijlstra JG, de Boer P, Spanjersberg R, Cohen Tervaert JW, van der Werf TS, et al. Suppression of the clinical and cytokine response to endotoxin by RWJ-67657, a p38 mitogen-activated protein-kinase inhibitor, in healthy human volunteers. Clin Exp Immunol 2001; 124(1): 16-20.
228. Fijen JW, Tulleken JE, Kobold AC, de Boer P, van der Werf TS, Ligtenberg JJ, et al. Inhibition of' p38 mitogen-activated protein kinase dose-dependent suppression of leukocyte and endothelial response after endotoxin challenge in humans. Crit Care Med 2002; 30(4): 841-5.
229. Bianchi M, Ulrich P, Bloom O, Meistrell M3, Zimmerman GA, Schmidtmayerova H, et al. An inhibitor of macrophage arginine transport and nitric oxide production (CNI-1493) prevents acute inflammation and endotoxin lethality. Mol Med 1995; 1(3): 254-66.
230. Cohen PS, Nakshatri H, Dennis J, Caragine T, Bianchi M, Cerami A, et al. CNI-1493 inhibits monocyte/macrophage tumor necrosis factor by suppression of translation efficiency. Proc Natl Acad Sci USA 1996; 93(9): 3967-71.
231. Bernik TR, Friedman SG, Ochani M, DiRaimo R, Ulloa L, Yang H, et al. Pharmacological stimulation of the cholinergic antiinflammatory pathway. J Exp Med 2002; 195(6): 781-8.
232. Akerlund K, Erlandsson Harris H, Tracey KJ, Wang H, Fehniger T, Klareskog L, et al. Anti-inflammatory effects of a new tumour necrosis factor-alpha (TNF-alpha) inhibitor (CNI-1493) in collagen-induced arthritis (CIA) in rats. Clin Exp Immunol 1999; 115(1): 32-41.
233. Denham W, Fink G, Yang J, Ulrich P, Tracey K, Norman J. Small molecule inhibition of tumor necrosis factor gene processing during acute pancreatitis prevents cytokine cascade progression and attenuates pancreatitis severity. Am Surg 1997; 63(12): 1045-9.
234. Denham W, Yang J, Wang H, Botchkina G, Tracey KJ, Norman J. Inhibition of p38 mitogen activate kinase attenuates the severity of pancreatitis-induced adult respiratory distress syndrome. Crit Care Med 2000; 28(7): 2567-72.
235. Hommes D, van den Blink B, Plasse T, Bartelsman J, Xu C, Macpherson B, et al. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease Gastroenterology 2002; 122(1): 7-14.
236. Rosenberg SA, Mule JJ, Spiess PJ, Reichert CM, Schwarz SL. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med 1985; 161(5): 1169-88.
237. Kammula US, White DE, Rosenberg SA. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer 1998; 83(4): 797-805.
238. Kemeny MM, Botchkina GI, Ochani M, Bianchi M, Urmacher C, Tracey KJ. The tetravalent guanylhydrazone CNI-1493 blocks the toxic effects of interleukin-2 without diminishing antitumor efficacy. Proc Natl Acad Sci USA 1998; 95(8): 4561-6.
239. Atkins MB, Redman B, Mier J, Gollob J, Weber J, Sosman J, et al. A phase I study of CNI-1493, an inhibitor of cytokine release, in combination with high-dose interleukin-2 in patients with renal cancer and melanoma. Clin Cancer Res 2001; 7(3): 486-92.
240. Bhalla US, Ram PT, Iyengar R. MAP kinase phosphatase as a locus of flexibility in a mitogen-activated protein kinase signaling network. Science 2002; 297(5583): 1018-23.
241. Gilman AG, Simon MI, Bourne HR, Harris BA, Long R, Ross EM, et al. Overview of the Alliance for Cellular Signaling. Nature 2002; 420(6916): 703-6.
242. Frame S, Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem J 2001; 359(Pt 1): 1-16.
243. Ohmachi M, Rocheleau CE, Church D, Lambie E, Schedl T, Sundaram MV. C. elegans ksr-1 and ksr-2 have both unique and redundant functions and are required for MPK-1 ERK phosphorylation. Curr Biol 2002; 12(5): 427-33.
244. Tanoue T, Maeda R, Adachi M, Nishida E. Identification of a docking groove on ERK and p38 MAP kinases that regulates the specificity of docking interactions. EMBO J 2001; 20(3): 466-79.
245. Kolch W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 2000; 351(Pt 2): 289-305.
246. Bell SM, Kelly SA, Hoyle JA, Lewis FA, Taylor GR, Thompson H, et al. c-Ki-ras gene mutations in dysplasia and carcinomas complicating ulcerative colitis. Br J Cancer 1991; 64(1): 174-8.
247. Anker P, Mulcahy H, Stroun M. Circulating nucleic acids in plasma and serum as a noninvasive investigation for cancer: time for large-scale clinical studies? Int J Cancer 2003; 103(2): 149-52.
248. Johnson PJ, Lo YM. Plasma nucleic acids in the diagnosis and management of malignant disease. Clin Chem 2002; 48(8): 1186-93.
249. Hu L, Hofmann J, Lu Y, Mills GB, Jaffe RB. Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 2002; 62(4): 1087-92.
250. Yung Y, Yao Z, Hanoch T, Seger R. ERK1b, a 46-kDa ERK isoform that is differentially regulated by MEK. J Biol Chem 2000; 275(21): 15799-808.
251. Jiang Y, Chen C, Li Z, Guo W, Gegner JA, Lin S, et al. Characterization of the structure and function of a new mitogen-activated protein kinase (p38beta). J Biol Chem 1996; 271(30): 17920-6.
252. Kumar S, McDonnell PC, Gum RJ, Hand AT, Lee JC, Young PR. Novel homologues of CSBP/p38 MAP kinase: activation, substrate specificity and sensitivity to inhibition by pyridinyl imidazoles. Biochem Biophys Res Commun 1997; 235(3): 533-8.
253. Lechner C, Zahalka MA, Giot JF, Moller NP, Ullrich A. ERK6, a mitogen-activated protein kinase involved in C2C12 myoblast differentiation. Proc Natl Acad Sci USA 1996; 93(9): 4355-9.
254. Li Z, Jiang Y, Ulevitch RJ, Han J. The primary structure of p38 gamma: a new member of p39 group of MAP kinases. Biochem Biophys Res Commun 1996; 228(2): 334-40.
255. Jiang Y, Gram H, Zhao M, New L, Gu J, Feng L, et al. Characterization of the structure and function of the fourth member of p38 group mitogen-activated protein kinases, p38delta. J Biol Chem 1997; 272(48): 30122-8.
256. Zhu AX, Zhao Y, Moller DE, Flier JS. Cloning and characterization of p97MAPK, a novel human homolog of rat ERK-3. Mol Cell Biol 1994; 14(12): 8202-11.
257. Turgeon B, Lang BF, Meloche S. The protein kinase ERK3 is encoded by a single functional gene: genomic analysis of the ERK3 gene family. Genomics 2002; 80(6): 673-80.
258. Gonzalez FA, Raden DL, Rigby MR, Davis RJ. Heterogeneous expression of four MAP kinase isoforms in human tissues. FEBS Lett 1992; 304(2-3): 170-8.
259. Zhou G, Bao ZQ, Dixon JE. Components of a new human protein kinase signal transduction pathway. J Biol Chem 1995; 270(21): 12665-9.
260. Lee JD, Ulevitch RJ, Han J. Primary structure of BMK1: a new mammalian map kinase. Biochem Biophys Res Commun 1995; 213(2): 715-24.
261. Dancey JE. Agents targeting ras signaling pathway. Curr Pharm Design 2002; 8(25): 2259-67.
262. Pullerits T. Cytokine modulation for anti-allergic treatment. Curr Pharm Design 2002; 8(20): 1845-53.
263. Szekely JI, Torok K, Mate G. The role of ionotropic glutamate receptors in nociception with special regard to the AMPA binding sites. Curr Pharm Design 2002; 8(10): 887-912.